Curis Q2 net loss $11.8M; emavusertib gets EU ODD for PCNSL

CURIS INC

2024-Q2 EPS reported -$4.08 revenue$4,632,000

Net loss of $11.8M ($2.03/sh) vs $12.0M ($2.47) in Q2 2023; revenue $2.5M from Erivedge royalties.
Cash, equivalents and investments $28.4M; expected to fund operations into Q1 2025.
EC granted Orphan Drug Designation to emavusertib for treatment of primary CNS lymphoma.
Initial data for 15-20 R/R PCNSL patients expected late 2024; ASH presentation planned.
Updated TakeAim Leukemia data and frontline triplet combo safety data due late 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.